[{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Revascor","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transendocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Mesoblast","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Remestemcel-L","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Mesoblast Limited","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast \/ Mesoblast Limited"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Cleveland Clinic"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Remestemcel-L","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":1.3600000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3600000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Novartis"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.11,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"Remestemcel-L","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3500000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Novartis"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Grunenthal"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"TNFR1","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-l","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Remestemcel-l","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"BMT CTN","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ BMT CTN","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ BMT CTN"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Gregory George"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Mesoblast
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
